KOSDAQBiotech & Pharma000250

Sam Chun Dang Pharm

₩140,700▼ 12.45%2026-11-18 close
Market Cap
₩3.3T
Turnover
₩151.7B
Volume
1.2M
Shares out.
23.5M
PER
311.8×
PBR
13.9×
EPS
₩574
Dividend Yield
0.03%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

Ophthalmic base expands; margins and pipeline await proof

SAM Chun Dang Pharm keeps growing revenue through its Eylea biosimilar and overseas sales, while its operating margin, at 3.7% in 2025, is recovering from the 2024 low and its oral platform programs remain in clinical and regulatory stages.

  1. 1

    Revenue rose from KRW 177.3 billion in 2022 to KRW 231.8 billion in 2025, and third-quarter 2026 revenue was up 19.2% year on year.

  2. 2

    Operating profit fell to KRW 2.64 billion in 2024 before recovering to KRW 8.47 billion in 2025, with a 3.7% operating margin in 2025.

  3. 3

    The company posted a third-quarter 2026 net loss attributable to controlling shareholders of KRW 1.81 billion, turning from a profit in the prior quarter.

  4. 4

    Overseas revenue in the first half of 2026 reached KRW 23.87 billion, up 155.2% year on year, or about 17.6% of consolidated revenue, according to the half-year report.

  5. 5

    Oral semaglutide has exclusive licensing and commercialization agreements with partners in the US and Europe, while oral insulin has a Phase 1/2 trial application filed in Europe.

02

Business structure

SAM Chun Dang Pharm was founded in 1943 and built its business around ophthalmic products. WiseReport, a corporate research provider, reported that ophthalmic preparations accounted for 67.5% of product sales, with circulatory drugs and antibiotics making up the rest.

Dailypharm reported that ophthalmic products rose to 60.76% of total revenue in the third quarter of 2026, and the two shares come from different measurement bases and periods.

Its ophthalmic subsidiary, in which the company holds a 44.5% stake as of November 2025, has long held a leading position in single-use eye drops in Korea. By a market tally cited by Yuvist, the company's share of the latanoprost single-use eye drop market rose from 3.1% in March 2025 to 11.0% in August 2026.

Its Eylea (aflibercept) biosimilar SCD411 completed a global Phase 3 trial, and sales began in Canada, Korea and Europe in 2025. Overseas sales run through local partners in each country, and the company has not disclosed individual partner names.

Its platform business includes oral semaglutide and oral insulin based on the S-PASS platform, long-acting injectables and subcutaneous reformulation. Production runs at the Hwaseong plant, which averaged a 69.2% utilization rate in 2025, with output down 10.4% from the prior year according to the annual report. Peers that combine biosimilars and platform businesses include Celltrion and Alteogen.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩58B₩3.4B5.9%
2025Q4₩66.3B₩5.4B8.2%
2026Q1₩64.9B₩5.4B8.4%
2026Q2₩70.7B₩3.4B4.9%
2026Q3₩69.2B₩3.5B5.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩177.3B₩12.2B₩5.8B6.9%3.4%52.0%
2023₩192.7B₩9.6B-₩10.4B5.0%−4.7%36.7%
2024₩210.9B₩2.6B-₩10.9B1.3%−4.1%48.8%
2025₩231.8B₩8.5B₩5.3B3.7%1.9%54.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a DART-filed basis, annual revenue rose from KRW 177.3 billion in 2022 to KRW 192.7 billion in 2023 (up 8.6%), KRW 210.9 billion in 2024 (up 9.5%) and KRW 231.8 billion in 2025 (up 9.9%), with growth in three consecutive years from 2023 through 2025.

Operating profit over the same period went from KRW 12.2 billion in 2022 to KRW 9.56 billion in 2023 (down 21.8%) and KRW 2.64 billion in 2024 (down 72.4%), before recovering to KRW 8.47 billion in 2025 (up 220.5%).

The operating margin was 6.9% in 2022, 5.0% in 2023, 1.3% in 2024 and 3.7% in 2025, so margins fell even as revenue grew until the 2025 rebound. Dailypharm reported that 2025 cost of sales reached KRW 111.3 billion, up 16%, and selling, general and administrative expenses reached KRW 97.0 billion, up 11%.

R&D intensity fell from 21.6% of revenue in 2022 to 12.24% in 2024, while third-quarter 2026 selling expenses rose 10.67% year on year to KRW 24.9 billion, with commission fees and market development costs also increasing.

Net income attributable to controlling shareholders went from KRW 5.84 billion in 2022 to a loss of KRW 10.4 billion in 2023, a loss of KRW 10.9 billion in 2024, and a profit of KRW 5.26 billion in 2025. Net income including non-controlling interests, at KRW 12 billion in 2025, is a different figure.

Quarterly operating profit was KRW 5.42 billion in the fourth quarter of 2025, KRW 5.45 billion in the first quarter of 2026, KRW 3.44 billion in the second quarter and KRW 3.55 billion in the third, so the second and third quarters both stayed in the KRW 3 billion range.

The first quarter of 2026 also absorbed a production halt at an overseas contract manufacturer from mid-February to late March for GMP compliance, along with logistics disruption.

The third-quarter 2026 net loss attributable to controlling shareholders of KRW 1.81 billion came after four quarters that totaled KRW 13.4 billion. Operating cash flow fell from KRW 21.8 billion in 2024 to KRW 9.79 billion in 2025.

05

Industry analysis

The company's core end markets are ophthalmology and biosimilars. Its annual report says the global age-related macular degeneration treatment market is expected to keep growing.

The same report projects that the insulin and GLP-1 based diabetes and obesity drug market will grow at about 14% a year, though this is the company's own projection rather than an independently verified market size.

In the Korean single-use eye drop market, the company's share rose sharply between March 2025 and August 2026, and its share of the clinic and hospital channel grew from 4.8% to 14.2%.

The Eylea biosimilar space is a competitive field, and the company's platform ambitions rely on oral conversion of injectable drugs using its own technology. On the cost side, the annual report cites drug pricing reform and rising input costs as pressures on profitability.

Dailypharm reported that the industry expects cost burdens from the early market launch of its Eylea biosimilar to persist for some time. Among listed peers, the company is compared with Celltrion, Samsung Biologics and Alteogen, but the gap in revenue scale and profit structure is wide.

06

Outlook

The nearest growth driver is the Eylea biosimilar SCD411. Approval procedures are complete in Japan and Europe, and the final US review aims for approval in the first half of 2027, while Korea has granted approval and commercial production is ready. A company official said European sales would ramp up in 2027.

In its first-quarter 2026 briefing in May, the company said delayed overseas volumes would be recognized from the second quarter and that earnings improvement would become clearer in the second half.

However, second-quarter 2026 operating profit fell from the prior quarter, and the third quarter turned into a net loss attributable to controlling shareholders.

On distribution, the company disclosed an agreement that adds six Middle East countries to its Canadian exclusive distribution rights for SCD411, and European market coverage is expanding. On the platform side, partners in the US and Europe are handling commercialization of oral semaglutide.

At CPHI Worldwide 2026 in Milan in October 2026, the company held about 120 partnering meetings with overseas pharma companies. Oral insulin has a Phase 1/2 trial application in Europe, and in a March 2026 report the company said results could be confirmed by the end of 2026 if the trial is approved.

In June 2026 the company announced a plan to buy back about 315,000 shares, which would lift its treasury stake from 0.01% to about 3.6% if completed.

07

Valuation

PER
311.8×
PBR
13.9×
ROE
4.7%
EPS
₩574
BPS
₩12,832
Dividend per share
₩50

Valuation reads differently depending on how far the share price sits above reported earnings. Over the last four quarters, net income attributable to controlling shareholders totaled KRW 13.4 billion, while the price-based earnings multiple sits well above the industry average.

The price-to-book ratio is at a large premium to net asset value. The dividend yield is below the industry average. At the end of 2025, equity attributable to controlling shareholders was KRW 276 billion and total equity was KRW 363.6 billion, and the market capitalization is far above that capital base.

One reading is that the market is pricing in future profits from overseas sales of the Eylea biosimilar and clinical results from the oral platform, while another is that the current earnings base is still thin.

The recovery in operating margin from 1.3% in 2024 to 3.7% in 2025 is a key indicator separating the two readings. With R&D intensity falling and selling expenses rising, whether margin recovery holds is the central variable behind any multiple-based interpretation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Biosimilar sales expanding abroad

Sales of the Eylea biosimilar began in Canada, Korea and Europe in 2025. Japan and Europe have completed approval procedures, and the US review targets approval in the first half of 2027. The company says European sales will ramp in 2027. Supporters argue that more markets could raise the overseas share of revenue.

Overseas revenue growth and return to profit

First-half 2026 overseas revenue reached KRW 23.87 billion, up 155.2% year on year. First-half operating profit was KRW 8.89 billion, turning from a loss in the prior-year period. Third-quarter 2026 revenue rose 19.2% year on year. Together with the 220.5% rise in 2025 operating profit, supporters cite this as evidence of earnings recovery.

Global partnerships for oral platforms

The oral semaglutide licensing scope now spans the US and 11 European countries including the UK. Supply agreements for SCD411 have expanded from Canada to six Middle East countries. Oral insulin has a Phase 1/2 trial application in Europe. Supporters argue that the platform could become a new growth axis if clinical data holds up.

09

Bear factors

Uncertain margin recovery

The operating margin fell from 6.9% in 2022 to 1.3% in 2024 and recovered to 3.7% in 2025, which is still low. Selling costs and market development expenses are rising quickly, and bears argue that revenue growth may not translate into profit. Dailypharm reported that profitability has been weakening for three years.

If the margin structure does not change, bears argue that top-line growth alone will not reach shareholder earnings.

Recent quarters show slowing profit and a loss

Second-quarter 2026 operating profit was KRW 3.44 billion, down 36.9% from the prior quarter. In the third quarter, net income attributable to controlling shareholders turned to a loss of KRW 1.81 billion from a profit in the prior quarter.

Dailypharm reported that the industry expects cost pressure from the early market rollout of the biosimilar to continue for some time. Bears argue that the recent quarters stalled before a recovery was confirmed.

Pipeline still awaiting clinical and regulatory proof

The commercial case for oral semaglutide, oral insulin and the platform technology has not yet been proven through clinical trials and approvals. A March 2026 news report said the share price was driven more by expectations for future value than by current earnings.

Bears argue that if expectations diverge from clinical results, price swings could widen. The concern is that the growth narrative runs ahead of reported earnings.

10

Risk factors

Production and supply disruption

In the first quarter of 2026, production at an overseas contract manufacturer stopped from mid-February to late March during a routine inspection. Geopolitical risk also disrupted the European export schedule. The company said delayed volumes would be recognized from the second quarter as supply normalized. As overseas production dependence rises, similar disruptions could recur.

Governance and share supply

As of September 11, 2026, the largest shareholder group and related parties held 37.61% of shares. In September 2025 the company issued exchangeable bonds with a face value of about KRW 29.5 billion. If conversion is requested, the share count could rise.

The company announced a treasury share buyback plan in June 2026. Ownership structure and share supply changes should be read together as factors behind price movement.

Share price volatility and external factors

The 52-week beta stands at 1.58, indicating larger price swings than the broader market. Drug pricing reform and rising costs could weigh on profitability. Logistics disruption in the Middle East and other regions could affect overseas supply. When these external factors coincide with earnings trends, share price reactions could become larger.

11

What to watch next

  1. Around March 2027

    The 2026 annual report will disclose full-year revenue, operating margin and fourth-quarter 2026 results. The prior annual report was filed on March 20, 2026.

  2. First half of 2027

    The final US review decision on SCD411 is expected. Approval and its timing will shape US sales scale and the overseas share of revenue.

  3. During 2027

    Checking whether European sales ramp-up translates into higher revenue and profit is the next step. Whether the operating margin rises above 3.7% from 2025 is the key test.

  4. End of December 2026

    Progress of the oral insulin Phase 1/2 trial, for which the company said in a March 2026 report that results could be confirmed by the end of the year if approved. Confirmation of trial approval and results would clarify the direction of the platform business.

12

Overall view

SAM Chun Dang Pharm combines revenue growth from its ophthalmic base with expanding overseas sales of its Eylea biosimilar. Annual revenue rose from KRW 177.3 billion in 2022 to KRW 231.8 billion in 2025, and operating profit recovered to KRW 8.47 billion in 2025 from the 2024 low.

However, the operating margin remains low at 3.7% in 2025, and the third quarter of 2026 turned into a net loss attributable to controlling shareholders. Overseas revenue rose 155.2% in the first half of 2026, while production disruption and higher selling costs appeared at the same time.

Oral semaglutide and oral insulin are at partnership and clinical stages, and their commercial case still needs clinical and regulatory proof. Supporting factors include more overseas markets and platform agreements, while the uncertain margin recovery and recent quarterly loss are the main drags.

The next checkpoints are the operating margin in the 2026 annual report, the US approval outcome and European sales results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 13 more articles and sources
  1. comp.wisereport.co.kr
  2. koreadaily.com
  3. pharmnews.com
  4. dailypharm.com
  5. kind.krx.co.kr
  6. m.healthcaren.com
  7. news.nate.com
  8. m.news.nate.com
  9. kr.investing.com
  10. dailypharm.com
  11. v.daum.net
  12. m.truefriend.com
  13. mt.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis